Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Breast cancer (BC) is a heterogeneous disease, encompassing a diverse spectrum of
tumours with varying morphological, biological, and clinical phenotypes. Although tumours …

Simple Summary The CREB-binding protein (CBP) and p300 are paralogous lysine
acetyltransferases that serve as critical co-activators for transcription factors involved in …

The causes and consequences of abnormal biogenesis of extracellular vesicles (EVs) are
not yet well understood in malignancies, including in breast cancers (BCs). Given the …

The progesterone receptor (PR) modulates estrogen receptors α (ERα) action in breast
cancer; it is an upregulated target gene of ER, and its expression is dependent on estrogen …

The evolving concept that cancer stem cells (CSCs) are the driving element in cancer
development, evolution and heterogeneity, has overridden the previous model of a tumor …

Background Abemaciclib is currently approved for the adjuvant treatment of high-risk, lymph
node (LN)-positive, hormone receptor (HR)-positive breast cancer (BC). In a real-world …

Abstract Introduction 16α-[18 F] Fluoroestradiol (FES), a PET radiotracer for the estrogen
receptor (ER) in breast cancer, was the first receptor-targeted PET radiotracer for oncology …

Breast cancer (BC) can be classified into various histological subtypes, each associated with
different prognoses and treatment options, including surgery, radiation, chemotherapy, and …